bioMerieux (OTCMKTS:BMXMF) Given Consensus Rating of “Reduce” by Analysts

bioMerieux (OTCMKTS:BMXMF) has been assigned an average rating of “Reduce” from the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company.

BMXMF has been the subject of several recent analyst reports. Piper Sandler initiated coverage on shares of bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Finally, UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st.

bioMerieux Stock Performance

OTCMKTS BMXMF opened at $79.32 on Tuesday. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average price of $85.69 and a 200 day moving average price of $106.28. bioMerieux has a 52 week low of $77.00 and a 52 week high of $152.00.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.